Biotechnology

Iovance Biotherapeautics

Mizuho and TD Cowen Maintain Buy Ratings for Iovance Biotherapeutics

H.C. Wainwright and Barclays Analysts Reiterate Buy Rating on Iovance Biotherapeutics

Iovance Biotherapeutics released FY2025 9 Months Earnings on November 6 Pre-Market (EST), actual revenue USD 176.73 M, actual EPS USD -0.9442

Iovance Biotherapeutics released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 67.46 M (forecast USD 72.81 M), actual EPS USD -0.2506 (forecast USD -0.2642)

Goonewardene rates Iovance Biotherapeutics as Strong Buy

Iovance Biotherapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 74.48M, EPS USD -0.2642

Iovance Biotherapeutics and InspiroGene Partner to Enhance Cell Therapy Accessibility for Advanced Melanoma Patients

Iovance Biotherapeutics Raises $350 Million Through Share Issuance

Iovance Biotherapeutics Updates on TIL Therapy Progress and Clinical Data

Vanguard Group Increases Holdings in Iovance Biotherapeutics in Q1

Iovance Biotherapeutics Inc's AMTAGVI® Approved by Health Canada for Advanced Melanoma

Iovance Biotherapeutics Forecasts Revenue Between $250M and $300M in 2025

Iovance Biotherapeutics released FY2025 Q2 earnings on August 7 After-Market (EST), actual revenue USD 59.95 M (forecast USD 67.14 M), actual EPS USD -0.3337 (forecast USD -0.2856)

Iovance Biotherapeutics released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 109.28 M, actual EPS USD -0.693

Iovance Biotherapeutics Reports Q2 2025 Earnings and Announces Strategic Restructuring

Iovance Biotherapeutics to release FY2025 Q2 earnings on August 7 After-Market EST, forecast revenue USD 67.14 M, EPS USD -0.2856

Iovance Biotherapeutics Shares Rise 32.8%

Iovance Biotherapeutics Appoints New CFO

DJS Law Firm Files Class Action Lawsuit Against Iovance for Misstatements

Iovance Biotherapeutics Showcases TIL Therapy Leadership

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap